Provided by Tiger Fintech (Singapore) Pte. Ltd.

Blueprint Medicines

89.58
-0.2600-0.29%
Post-market: 89.580.00000.00%16:23 EDT
Volume:669.70K
Turnover:59.83M
Market Cap:5.72B
PE:-83.93
High:90.84
Open:90.44
Low:88.00
Close:89.84
Loading ...

Company Profile

Company Name:
Blueprint Medicines
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
649
Office Location:
45 Sidney Street,Cambridge,Massachusetts,United States
Zip Code:
02139
Fax:
- -
Introduction:
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Directors

Name
Position
Daniel S. Lynch
Chairman and Director
Jeffrey W. Albers
President,Chief Executive Officer and Director
Alexis Borisy
Director
Charles A. Rowland, Jr.
Director
George D. Demetri
Director
Lonnel Coats
Director
Lynn Seely
Director
Mark Goldberg
Director
Nicholas Lydon
Director

Shareholders

Name
Position
Jeffrey W. Albers
President,Chief Executive Officer and Director
Christopher K. Murray
Senior Vice President, Technical Operations
Anthony L. Boral
Chief Medical Officer
Kathryn Haviland
Chief Business Officer
Marion Dorsch
Chief Scientific Officer
Michael Landsittel
Vice President, Finance
Tracey L. McCain
Chief Legal and Compliance Officer